FT商学院

Drugmaker Eisai secures ESG money by linking investments to value

‘Hard numbers’ model designed by ex-head of finance is winning followers among leading investors and corporate Japan

You could be forgiven for expecting a former chief financial officer at Eisai, a conservative, family-run Japanese pharmaceutical company, to be a buttoned-up number-cruncher. You might imagine someone focused solely on obscure financial metrics, earnings reports, and margin calculations.

But, while Ryohei Yanagi’s job at Eisai certainly required an appetite for such dry fare, he is also something of a maverick. For 15 years, he has surveyed close to 200 leading investors about corporate governance, as well as social and environmental issues in Japan. He did this long before ESG became a buzzword repeated on every earnings call.

One finding that stands out in his research is that the number of investors wanting companies to explain better how their ESG activities contribute to the bottom line has nearly doubled in the past six years. At the same time, the proportion of respondents saying ESG does not matter has fallen from a quarter to nearly zero.

您已阅读17%(960字),剩余83%(4654字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归manbetx20客户端下载 所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。
设置字号×
最小
较小
默认
较大
最大
分享×